MRK Stock Recent News

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. HYPERION met its primary endpoint of time to clin.

Investors love growth stocks that also pay big and reliable dividends because they provide dependable passive income streams and an excellent opportunity for solid total return.

Merck (MRK) closed at $79.29 in the latest trading session, marking a +1.29% move from the prior day.

U.S. Health Secretary Robert F. Kennedy Jr. is considering asking a key government vaccine advisory panel to examine vaccines that contain aluminum ingredients, Bloomberg News reported on Wednesday, citing a source familiar with the matter.

A revamped government panel of vaccine advisors appointed by Health and Human Services Secretary Robert F. Kennedy Jr. will soon vote on a shot preservative that contains mercury, which is safely used in some flu jabs but has been incorrectly linked to autism in the past.

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) with disease progression during or after treatment with an androgen receptor pathway inhibitor. Ifinatamab deruxtecan is a specifically engineered, potential first-in-class B7-H3 directed DXd antibody.

There are excellent reasons to invest in dividend stocks, including the fact that they typically outperform their non-dividend-paying peers in delivering strong market returns over long periods.

Merck's Gardasil sales decline due to weak demand trends in China, with new launches expected to offset the downside.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

High quality doesn't have to come at a high price. I highlight 2 moat-worthy stocks that are trading far below historical valuations. Both carry strong operating fundamentals and pay well-covered dividends, resulting in a dislocation between value and price.